Feb 2 (Reuters) - Braeburn Pharmaceuticals Inc, the maker of
the first long-acting implant to treat opioid addiction in the
United States, said on Thursday that it had decided not to
proceed with its initial public offering, citing current market
environment.
Read more
No comments:
Post a Comment